Cantor Fitzgerald cut shares of TESARO (NASDAQ:TSRO) from an overweight rating to a neutral rating in a report released on Wednesday morning, The Fly reports.
A number of other brokerages also recently issued reports on TSRO. Evercore ISI downgraded shares of TESARO to an outperform rating in a research report on Tuesday. HC Wainwright reaffirmed a buy rating and issued a $69.00 price objective on shares of TESARO in a research report on Monday, December 3rd. Wells Fargo & Co downgraded shares of TESARO from an outperform rating to a market perform rating in a research report on Monday, December 3rd. Robert W. Baird set a $75.00 price objective on shares of TESARO and gave the stock a hold rating in a research report on Monday, December 3rd. Finally, SunTrust Banks downgraded shares of TESARO from a buy rating to a hold rating and lifted their price objective for the stock from $65.00 to $75.00 in a research report on Monday, December 3rd. Fifteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. TESARO presently has a consensus rating of Hold and an average target price of $78.18.
Shares of TESARO stock opened at $73.95 on Wednesday. The company has a debt-to-equity ratio of 3.74, a current ratio of 3.40 and a quick ratio of 2.83. TESARO has a 52-week low of $23.41 and a 52-week high of $85.48.
Large investors have recently added to or reduced their stakes in the business. US Bancorp DE grew its position in TESARO by 163.5% during the 3rd quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 2,445 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in TESARO during the 2nd quarter valued at approximately $257,000. New Jersey Better Educational Savings Trust acquired a new stake in TESARO during the 3rd quarter valued at approximately $234,000. BTG Pactual Global Asset Management Ltd acquired a new stake in TESARO during the 2nd quarter valued at approximately $277,000. Finally, Pacer Advisors Inc. acquired a new stake in TESARO during the 3rd quarter valued at approximately $273,000.
TESARO Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
See Also: How Do I Invest in Dividend Stocks
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.